Dementia with Lewy bodies: Molecular pathogenesis and implications for classification

Journal of Geriatric Psychiatry and Neurology

Volumn 17, Issue 3, 2004, Pages 112-119

  Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dementia with Lewy bodies; Molecular pathogenesis

Indexed keywords

BEHAVIOR DISORDER; BRAIN CORTEX; CELL DAMAGE; COGNITIVE DEFECT; CORRELATION ANALYSIS; CYTOPLASM; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; LEWY BODY; NERVE DEGENERATION; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FOLDING; PSYCHOSIS; REM SLEEP; REVIEW; VISUAL HALLUCINATION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LEWY BODY DISEASE; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PROTEIN CONFORMATION; SEVERITY OF ILLNESS INDEX;

EID: 4344560385     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/0891988704267473     Document Type: Review

References (55)

1. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302:819-822.
2. Dickson D. A-synuclein and the Lewy body disorders. Curr Opin Neurol 2001; 14:423-432.
3. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292:1552-1555.
4. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev 2002; 3:1-11.
5. Cummings JL. Towards a molecular neuropsychiatry of neurodegenerative diseases. Ann Neurol 2003; 54:147-154.
6. Hardy J, Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science 1998; 282:1075-1079.
7. Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 1998; 282:1072-1074.
8. Martin JB, Longo FM. Molecular neurobiology. In: Jameson LJ, ed. Principles of molecular medicine. Totowa, NJ: Humana Press, 1998:871-890.
9. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002; 296:1991-1995.
10. Trojanowski JQ, Lee VM-Y. "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann N Y Acad Sci 2000; 924:62-67.
11. Lovestone S, McLoughlin DM. Protein aggregates and dementia: is there a common toxicity? J Neurol Neurosurg Psychiatry 2002; 72:152-161.
12. Walker LC, LeVine H 3rd. The cerebral proteopathies. Neurobiol Aging 2000; 21:559-561.
13. Ganesh S, Delgado-Escueta AV, Suzuki T, et al. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum Mol Genet 2002; 11:1263-1271.
14. Stumpf E, Masson H, Duquette A, et al. Adult Alexander disease with autosomal dominant transmission: a distinct entity caused by mutation in the glial fibrillary acid protein gene. Arch Neurol 2003; 60:1307-1312.
15. Forman MS, Lee VM, Trojanowski JQ. 'Unfolding' pathways in neurodegenerative disease. Trends Neurosci 2003; 26:407-410.
16. Trivedi JR, Wolfe GI, Nations SP, et al. Adult polyglucosan body disease associated with Lewy bodies and tremor. Arch Neurol 2003; 60:764-766.
17. Bradshaw CB, Davis RL, Shrimpton AE, et al. Cognitive deficits associated with a recently reported familial neurodegenerative disease. Arch Neurol 2001; 58:1429-1434.
18. Davis RL, Shrimpton AE, Holohan PD, et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 1999; 401:376-379.
19. Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002; 3:759-768.
20. Saito Y, Suzuki K, Nanba E, et al. Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity. Ann Neurol 2002; 52:351-355.
21. Dobson CM. Protein folding and disease: a view from the first Horizon Symposium. Nat Rev Drug Discov 2003; 2:154-160.
22. Wolozin B, Behl C. Mechanisms of neurodegenerative disorders part 1: protein aggregates. Arch Neurol 2000; 57:793-796.
23. Wolozin B, Behl C. Mechanisms of neurodegenerative disorders part 2: control of cell death. Arch Neurol 2000; 57:801-804.
24. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416:507-511.
25. Golbe LI. Neurodegeneration in the age of molecular biology. Br Med J 2002; 324:1467-1468.
26. Brookes AJ, St Clair D. Synuclein proteins and Alzheimer's disease. Trends Neurosci 1994; 17:404-405.
27. Lippa CF, Schmidt ML, Lee VM, et al. Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol 2001; 58:1817-1820.
28. Lippa CF, Schmidt ML, Lee VM, et al. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 1999; 45:353-357.
29. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113-1124.
30. Masliah E, Rockenstein E, Veinbergs I, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001; 98:12245-12250.
31. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003; 300:636-640.
32. Oddo S, Caccarno A, Kitazawa M, et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003; 24:1063-1070.
33. Braak H, De Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211.
34. Cummings JL, Cole G. Alzheimer's disease. JAMA 2002; 287:2335-2338.
35. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: Diagnosis and treatment. Neurology 1999; 53:902-905.
36. Cummings JL. Conference summary: Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease Dementia. Reviews in Neurological Disease, in press.
37. Duda JE, Giasson BI, Mabon ME, et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002; 52:205-210.
38. Rub U, Del Tredici K, Schultz C, et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 2002; 23:245-254.
39. Spillantini MG, Schimdt ML, Lee VM-Y, et al. A-synuclein in Lewy bodies. Nature 1997; 388:839-840.
40. Trojanowski JQ, Lee VM. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998; 55:151-152.
41. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003; 61:40-45.
42. Turner RS. Idiopathic rapid eye movement sleep behavior disorder is a harbinger of dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2002; 15:195-199.
43. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997; 49:1570-1576.
44. Mattila PM, Rinne JO, Helenius H, et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000; 100:285-290.
45. Hurtig H, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54:1916-1921.
46. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59:1714-1720.
47. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996; 40:767-775.
48. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55:164-173.
49. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
50. Payami H, Lee N, Zareparsi S, et al. Parkinson's disease, CYP2D6 polymorphism, and age. Neurology 2001; 56:1363-1370.
51. Tan EK, Chai A, Teo YY, et al. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 2004; 62:128-131.
52. Mizuno Y, Hattori N, Mori H, et al. Parkin and Parkinson's disease. Curr Opin Neurol 2001; 14:477-482.
53. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in Parkin gene. N Engl J Med 2000; 342:1560-1567.
54. Hardy J, Cookson MR, Singleton A. Genes and parkinsonism. Lancet Neurol 2003; 2:221-228.
55. Lansbury PT Jr, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Cell Biol 2002; 14:653-660.